Company* (Country; Symbol)Company (Country; Symbol)Type/Product AreaTerms/Details (Date)

I. MODIFIED AGREEMENTS
Alnylam Pharmaceuticals Inc. (ALNY)Medtronic Inc. (NYSE:MDT)Expanded deal to develop drug-device combination products utilizing RNAi to treat central nervous system diseasesThe original deal called for Alnylam to handle discovery and early development work while Medtronic would manage late-stage trials and commercialization; Medtronic would pay milestones and royalties; now, the deal is a 50/50 co-development and profit sharing arrangement in the U.S.; Alnylam has the opportunity to invest in clinical development; in Europe, Medtronic will handle development and commercialization and will pay Alnylam royalties (7/30)
Archemix Corp.*SomaLogic Inc.*Expanded alliance focused on the use and development of aptamers for therapeutic, diagnostic and other applicationsArchemix received exclusive rights to therapeutic uses of aptamers discovered by SomaLogic for a limited number of targets; SomaLogic will receive rights to all ex vivo uses of aptamers it did not previously hold, including the use of aptamers for affinity purification (8/8)
Exact Sciences

Corp. (EXAS)

Laboratory Corp. of America Holdings (NYSE:LH)Expanded licensing agreement for broader distribution of Exact's DNA technology for colorectal cancer screeningExact agreed to extend LabCorp's exclusivity period through 2010 in exchange for other terms (6/28)
Silence Therapeutics plc* (UK)Quark Pharmaceuticals Inc.*Expanded technology license agreement to provide Quark with options to nonexclusive licenses to develop additional molecules against three specific targets using Silence's AtuRNAi technologyThe original deal, signed in April 2005, provided Quark with access to the technology to develop RTP801i; under the expanded agreement, Silence is entitled to milestone payments and a royalty on product sales (7/31)
Tercica Inc. (TRCA)Genentech Inc.(NYSE:DNA)Expanded collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiencyThe deal could be worth up to $53M to Tercica, including $13M in equity investments, as well as opt-in payments, reimbursements and milestone payments (7/11)
II. TERMINATED AGREEMENTS
Anadys Pharmaceuticals Inc. (ANDS)LG Life Sciences* (South Korea)Temrinated agreement for the hepatitis B drug ANA360The company terminated the program in order to refocus resources on ANA598, an antiviral for hepatitis C, and ANA773, a TLR7 agonist prodrug for cancer (8/2)
The Medicines Co. (MDCO)Nycomed A/S* (Denmark)The Medicines Co. reacquired all European development and commercial rights to Angiox (bivalirudin)The company plans to sell the product itself in Europe; Nycomed gets $20M up front and $20M next year, and would get another $5M if European regulators approve an expanded Angiox label (7/2)
Viragen Inc. (AMEX:VRA)Oxford Biomedica plc (UK; LSE:OXB)Viragen halted development of its OVA avian transgenic protein manufacturing technology leading to the termination of its agreements with Oxford Biomedica and the Roslin InstituteViragen decided to stop development because of the large gap between research and commercialization (6/22)

Notes:
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange.

No Comments